PDS Biotechnology Corp — Director's Dealing 2016

Jun 23, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2016-06-21

Reporting Person: Conti Kurt G (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-21	Stock Option (right To Purchase)	$9.34	A	15000	Acquired	2026-06-21	Common Stock (15000)	Direct